Pharmacokinetics of Gemcitabine and 2',2'-Difluorodeoxyuridine in a Patient with Ascites
| Autor: | Ramesh K. Ramanathan, Merrill J. Egorin, William Plunkett, Brian J. Delauter, Lori L. Stover, Eleanor G. Zuhowski, William C. Zamboni |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Antimetabolites
Antineoplastic medicine.medical_specialty Metabolite medicine.medical_treatment Adenocarcinoma Pharmacology Deoxycytidine chemistry.chemical_compound Catheters Indwelling Pharmacokinetics Internal medicine Blood plasma Ascites medicine Humans Pharmacology (medical) Chromatography High Pressure Liquid Chemotherapy business.industry Middle Aged Prodrug Gemcitabine Abdominal Pain Pancreatic Neoplasms Endocrinology chemistry Effusion Urinary Tract Infections Female Fluorouracil medicine.symptom Floxuridine business medicine.drug |
| Zdroj: | Pharmacotherapy. 20:1204-1207 |
| ISSN: | 0277-0008 |
| Popis: | Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU). The pharmacokinetics of dFdC and dFdU have been studied; however, their disposition has never been evaluated in a patient with ascites. A patient with pancreatic cancer and malignant ascites was treated with dFdC 1500 mg/m 2 over 150 minutes weekly for 3 weeks, repeated every 4 weeks. Serial plasma and ascites samples were obtained on weeks 1 and 2 of cycle 2. High-pressure liquid chromatography was used to quantify dFdC and dFdU in plasma and ascites. The systemic dispositions of dFdC and dFdU were similar to those reported in patients without ascites. The concentration of dFdC in ascites approached 1 mg/ml. Ascitic fluid did not serve as a depot for dFdC, and the agent's concentration in ascites approached that at which its phosphorylation is saturated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text